AU2003247525A1 - Inhibitors of inflammatory gene activity and cholesterol biosynthesis - Google Patents

Inhibitors of inflammatory gene activity and cholesterol biosynthesis Download PDF

Info

Publication number
AU2003247525A1
AU2003247525A1 AU2003247525A AU2003247525A AU2003247525A1 AU 2003247525 A1 AU2003247525 A1 AU 2003247525A1 AU 2003247525 A AU2003247525 A AU 2003247525A AU 2003247525 A AU2003247525 A AU 2003247525A AU 2003247525 A1 AU2003247525 A1 AU 2003247525A1
Authority
AU
Australia
Prior art keywords
promoter
shp
gene
composition
detectable substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003247525A
Other languages
English (en)
Inventor
Mark J. Evans
Douglas C. Harnish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC, Wyeth LLC filed Critical Wyeth Holdings LLC
Publication of AU2003247525A1 publication Critical patent/AU2003247525A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003247525A 2002-06-13 2003-06-13 Inhibitors of inflammatory gene activity and cholesterol biosynthesis Abandoned AU2003247525A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
USNOTGIVEN 1999-11-30
US38791502P 2002-06-13 2002-06-13
US60/387,915 2002-06-13
PCT/US2003/018651 WO2003106632A2 (fr) 2002-06-13 2003-06-13 Inhibiteurs de l'activite genique inflammatoire et de la synthese de cholesterol

Publications (1)

Publication Number Publication Date
AU2003247525A1 true AU2003247525A1 (en) 2003-12-31

Family

ID=29736382

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003247525A Abandoned AU2003247525A1 (en) 2002-06-13 2003-06-13 Inhibitors of inflammatory gene activity and cholesterol biosynthesis

Country Status (4)

Country Link
AU (1) AU2003247525A1 (fr)
IL (1) IL165692A0 (fr)
WO (1) WO2003106632A2 (fr)
ZA (1) ZA200500296B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060233873A1 (en) * 2003-01-24 2006-10-19 Julien Meissonnier Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109467A1 (en) * 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
US20030083484A1 (en) * 2001-07-31 2003-05-01 Crooke Rosanne M. Antisense modulation of short heterodimer partner-1 expression

Also Published As

Publication number Publication date
ZA200500296B (en) 2005-11-01
IL165692A0 (en) 2006-01-15
WO2003106632A3 (fr) 2004-06-10
WO2003106632A2 (fr) 2003-12-24

Similar Documents

Publication Publication Date Title
Shi et al. 1α, 25‐dihydroxyvitamin D3 inhibits uncoupling protein 2 expression in human adipocytes
Kim et al. The adipose tissue triglyceride lipase ATGL/PNPLA2 is downregulated by insulin and TNF-α in 3T3-L1 adipocytes and is a target for transactivation by PPARγ
Fukui et al. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice.
Cheng et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells
Stein et al. Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure
EP2024511B1 (fr) Complexe de sirt1 et lxr regulant le cholesterol et procedes d'utilisation
EP2146724A2 (fr) Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
Jeong et al. A Newly Identified CG301269 Improves Lipid and Glucose Metabolism Without Body Weight Gain Through Activation of Peroxisome Proliferator–Activated Receptor α and γ
Baum et al. Aquaporin-1 gene transfer to correct radiation-induced salivary hypofunction
Duan et al. Upregulation of miR-133a by adiponectin inhibits pyroptosis pathway and rescues acute aortic dissection
Araya et al. Hormonal regulation of the human sterol 27-hydroxylase gene CYP27A1
US20050221328A1 (en) Inhibitors of inflammatory gene activity and cholesterol biosynthesis
Ro et al. Adipocyte enhancer‐binding protein 1 modulates adiposity and energy homeostasis
Gu et al. Administration of USP7 inhibitor P22077 inhibited cardiac hypertrophy and remodeling in Ang II-induced hypertensive mice
JP2002514908A (ja) うっ血性心不全のための遺伝子治療
AU2003247525A1 (en) Inhibitors of inflammatory gene activity and cholesterol biosynthesis
Makino et al. A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at-420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes
US6316258B1 (en) Methods for preventing and treating fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGFβ using renin inhibitors
JP2003061688A (ja) ５−リポキシゲナーゼ活性化タンパク質ｉｉ
Yamaguchi et al. Formula diet is effective for the reduction and differentiation of visceral adipose tissue in Zucker fatty rats
Ylitalo et al. C3, hormone-sensitive lipase, and peroxisome proliferator-activated receptor [gamma] expression in adipose tissue of familial combined hyperlipidemia patients
Oana et al. DNA microarray analysis of white adipose tissue from obese (fa/fa) Zucker rats treated with a β3-adrenoceptor agonist, KTO-7924
CN113692284A (zh) 用于治疗和预防心力衰竭的松弛素受体1
JP2010502985A (ja) インスリン感受性の制御におけるリポカリン２の使用
US20070258961A1 (en) Cholesterol efflux and uses thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted